Effectiveness of Using Nucleic Acid Amplification Test to Screen Blood Donors for Hepatitis B, Hepatitis C, and HIV: A Tertiary Care Hospital Experience From Pakistan

• Published in: Curēus (Palo Alto, CA) Vol. 15; no. 1; p. e34216
• Main Authors: Ali, Syeda M, Raza, Naila, Irfan, Muhammad, Mohammad, Mahnoor F, Kazmi, Fatima H, Fatima, Zainab
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 25.01.2023; Cureus
• Subjects: Acids; Automation; Blood & organ donations; Blood banks; Hematology; Hepatitis B; Hepatitis C; HIV; Hospitals; Human immunodeficiency virus; Immunoassay; Infections; Infectious Disease; Malaria; Serology; Syphilis; Viral infections; Viruses; Karachi Pakistan; Pakistan; hcv; transfusion-transmitted infections; hiv; hbv; nucleic acid amplification test
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.34216

Background Ensuring blood safety is the primary goal of transfusion medicine. Despite extensive serological tests and strict safety measures, the risk of transfusion-transmitted infections (TTIs) still exists. As applied to blood screening, Nucleic Acid Amplification Test (NAT) offers much higher sensitivity for detecting viral infections. It is, however, currently available to a handful of centers due to the high cost. This study aims to establish the Effectiveness of NAT by assessing the NAT yield and residual risk of transmission of Hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV with and without NAT testing. Material and method This prospective cross-sectional study recruited blood donors from January 2020 to November 2022. All donors underwent routine serologic screening. Only serologically negative donors were tested for HBV, HCV, and HIV by NAT. The NAT yield and residual risk (RR) per million donors were computed for viral infections in seronegative blood donors and calculated using the incidence/window period model. Result A total of 59708 donors were included during the study period. The overall prevalence of TTI's were: For HCV 1.7% (n = 1018), HBV 1.5% (n = 918), HIV 0.07% (n = 47), Syphilis 1.2% (n = 758) and malaria 0.3% (n = 218). Out of 57759 seronegative donors, thirty-four NAT-reactive samples were identified, with 3 cases of HCV, 31 cases of HBV, and Nil HIV cases. NAT yield of HBV was 1 in 1863 with an RR of 8.6 per million, followed by HCV with a NAT yield of 1 in 19253 and RR of 0.8 per million donations. NAT testing reduced RR for HBV by 48.9% and HCV by 94.5%. Conclusion Our study showed that NAT detected 34 out of 57759 cases initially missed by serological tests. The study suggests that the parallel use of serology and NAT screening of donated blood would be beneficial.